Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases
Author(s) -
Ruth Webster,
Adrianna Murphy,
Helen Bygrave,
Éimhín Ansbro,
Diederick E. Grobbee,
Pablo Perel
Publication year - 2020
Publication title -
global heart
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 37
eISSN - 2211-8179
pISSN - 2211-8160
DOI - 10.5334/gh.860
Subject(s) - medicine , fixed dose combination , listing (finance) , decentralization , government (linguistics) , control (management) , task (project management) , intensive care medicine , disease control , risk analysis (engineering) , process management , pharmacology , business , finance , environmental health , computer science , management , linguistics , philosophy , artificial intelligence , political science , law , economics
Highlights: - Despite clinical evidence of its effectiveness in secondary prevention of cardiovascular disease, uptake of fixed dose combination therapy (FDCs) for CVD has been poor. - A symposium was held bringing together stakeholders on this issue, including from academia, government and NGOs. - The conclusion made was that what is now needed to improve implementation of FDCs is country-specific health systems analyses to design appropriate implementation strategies. - Implementation strategies must look beyond listing on the WHO Essential Medicines List to consider approaches to improving FDC availability, accessibility, affordability, and adherence. - Strategies might include incorporation of FDCs into the WHO HEARTS technical package, simplified treatment and monitoring algorithms, decentralisation of medicine dispensing and task-sharing for treatment management.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom